AFA-281
Chronic Pain & Epilepsy
Phase 2Active
Key Facts
About AfaSci
AfaSci is a unique, self-sustaining biotech holding group with three synergistic business lines: therapeutic development (AfaSci Therapeutics), preclinical contract research services (AfaSci Research Laboratories), and research instrumentation (AfaSci Instruments). Its lead asset, AFA-281, is a Phase I-completed, novel dual-mechanism small molecule for chronic pain and epilepsy, protected by composition of matter patents in 16 countries. The company is currently seeking investment and partnerships to advance AFA-281 into Phase II proof-of-concept studies, with a potential exit via M&A upon successful trial results.
View full company profile